Novel 4-aminopyrazolo[3,4-b]pyridine PDE4 inhibitors

Abstract

Novel 4-alkylaminopyrazole[3,4-b]pyridine-5-carboxylate and 5-carboxamide derivatives are claimed. The claimed compounds are selective phosphodiesterase-4 (PDE4) inhibitors with good potency (0.1 – 100 nM) as inhibitors of PDE4B, and good oral activity in animal models of inflammation. The claimed compounds are reported to be less prone to induced emesis than other PDE4 inhibitors and, thus to have superior therapeutic ratios.

• asthma
• COPD
• inflammation
• neutrophil
• PDE4B
• PDE4D
• PDE4 inhibitor